Plain language summary
Crohn’s disease and ulcerative colitis are inflammatory bowel diseases that lead to symptoms of diarrhoea, bleeding and abdominal pain. Specialised treatments like biological drugs which are antibody treatments are available for the treatment of inflammatory Bowel Disease. We think that treating patients until they reach remission is most important as this is linked with best patient-related outcome.
This study is looking to compare the typical outcomes of patients, such as hospitalisation or surgery, who responded to the first biologic they had compared to those who have had a number of biologics because they didn’t respond. We hope that doing this study will provide evidence of the importance of identifying the most beneficial drug for a patient as early as possible. We will be requesting data relevant to patient age, gender and ethnicity, the level of complexity of their inflammatory bowel disease and the different treatments they had.
